跳至内容
Endocannabinoid regulation of monoamines in psychiatric and neurological disorders 線上預覽
關閉線上預覽
正在查...

Endocannabinoid regulation of monoamines in psychiatric and neurological disorders

作者: Elisabeth J Van Bockstaele
出版商: New York : Springer, ©2013.
版本/格式:   電子書 : 文獻 : 英語所有版本和格式的總覽
資料庫:WorldCat
提要:
The past two decades have seen a tremendous growth in knowledge related to cannabinoid receptor signaling in brain. In addition, the impact and consequences of cannabinoid modulation of monoaminergic circuits is steadily emerging demonstrating a significant interaction between these two systems in a variety of psychiatric (affective disorders) and neurological disorders (multiple sclerosis, pain). Despite increasing  再讀一些...
評定級別:

(尚未評分) 0 附有評論 - 成爲第一個。

主題
更多類似這樣的

 

在線上查詢

與資料的連結

在圖書館查詢

&AllPage.SpinnerRetrieving; 正在查詢有此資料的圖書館...

詳細書目

類型/形式: Electronic books
therapeutic use
drug therapy
其他的實體格式: Print version:
Endocannabinoid regulation of monoamines in psychiatric.
[S.l.] : Springer-Verlag New York, 2013
(OCoLC)841520677
資料類型: 文獻, 網際網路資源
文件類型: 網路資源, 電腦資料
所有的作者/貢獻者: Elisabeth J Van Bockstaele
ISBN: 9781461479406 1461479401 1461479398 9781461479390
OCLC系統控制編碼: 852471079
注意: Includes index.
描述: 1 online resource.
内容: Endocannabinoids and monoamines: modulating the modulators --
Endocannabinoid-mediated synaptic plasticity --
Current cannabinoid receptor nomenclature and pharmacological principles --
Cue-elicited craving for cannabis activates the reward neurocircuitry associated with the neuropathology of addiction --
Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders --
Pathophysiology of mood disorders and mechanisms of action of antidepressants and mood stabilizers --
Anatomical, biochemical and behavioral evidence for cannabinoid modulation of noradrenergic circuits: role of norepinephrine in cannabinoid-induced aversion --
Gender Disparity of Depression: The Role of Endocannabinoids and Noradrenergic Function --
Endocannabinoids, Monoamines and Stress --
Chronic effects of cannabinoid drugs on monoaminergic systems and the role of endocannabinoids and cannabinoid receptors in human brain disorders --
Endocannabinoid Signaling and the Regulation of the Serotonin System --
Modulation of serotonin firing activity through CB1 agonists and FAAH inhibitors --
Involvement of serotonergic system in cannabinoid analgesia --
Cannabinoids, monoamines, COMT and schizophrenia: pathobiological mechanisms in psychosis.
責任: Elisabeth J. van Bockstaele, editor.
更多資訊:

摘要:

Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders  再讀一些...

評論

社評

出版商概要

From the reviews: "This book reviews the expansion of our understanding of cannabinoid modulation of monoaminergic circuits and their interactions in a variety of psychiatric and neurological 再讀一些...

 
讀者提供的評論
正在擷取GoodReads評論...
正在擷取DOGObooks的評論

標籤

成爲第一個
確認申請

你可能已經申請過這份資料。若還是想申請,請選確認。

連結資料


<http://www.worldcat.org/oclc/852471079>
library:oclcnum"852471079"
library:placeOfPublication
library:placeOfPublication
rdf:typeschema:Book
rdf:typeschema:MediaObject
rdf:valueUnknown value: dct
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:copyrightYear"2013"
schema:datePublished"2013"
schema:description"The past two decades have seen a tremendous growth in knowledge related to cannabinoid receptor signaling in brain. In addition, the impact and consequences of cannabinoid modulation of monoaminergic circuits is steadily emerging demonstrating a significant interaction between these two systems in a variety of psychiatric (affective disorders) and neurological disorders (multiple sclerosis, pain). Despite increasing evidence from preclinical data suggesting that therapeutic use of cannabinoid-based drugs may outweigh any potential risks in certain serious medical conditions, the debate surrounding its widespread utility continues as regulatory concerns preclude a smooth transition of promising preclinical studies into clinical trial testing. This may persist in the near future as state and federal governments debate over regulation of medicinal applications of cannabis. Applications for medicinal cannabinoids that are already under investigation include the treatment of nausea, anorexia, neurodegeneration, inflammation, excitotoxicity and pain. The appetitive and anti-emetic properties of cannabinoids have led to the approval of their use in chemotherapy and AIDS patients. There is growing evidence for therapeutic cannabinoid effects on inflammatory and excitotoxic cellular processes that are linked to epilepsy, Parkinson's disease, amyotrophic lateral sclerosis, spasticity, and central nervous system injury. The chapters, herein, review and discuss current insights into the brain endocannabinoid system, cannabinoid receptor signaling on synaptic plasticity, potential therapeutic applications with a particular focus on endocannabinoid modulation of dopaminergic, noradrenergic and serotonergic circuitry. The potential for establishing cannabinoid-monoaminergic interactions as a novel target in the development of improved treatment strategies for psychiatric and neurological disorders is promising and will require future clinical studies to determine whether promising pre-clinical findings translate into new therapies."
schema:description"Endocannabinoids and monoamines: modulating the modulators -- Endocannabinoid-mediated synaptic plasticity -- Current cannabinoid receptor nomenclature and pharmacological principles -- Cue-elicited craving for cannabis activates the reward neurocircuitry associated with the neuropathology of addiction -- Cannabinoid modulation of dopaminergic circuits in neurodegenerative and neuropsychiatric disorders -- Pathophysiology of mood disorders and mechanisms of action of antidepressants and mood stabilizers -- Anatomical, biochemical and behavioral evidence for cannabinoid modulation of noradrenergic circuits: role of norepinephrine in cannabinoid-induced aversion -- Gender Disparity of Depression: The Role of Endocannabinoids and Noradrenergic Function -- Endocannabinoids, Monoamines and Stress -- Chronic effects of cannabinoid drugs on monoaminergic systems and the role of endocannabinoids and cannabinoid receptors in human brain disorders -- Endocannabinoid Signaling and the Regulation of the Serotonin System -- Modulation of serotonin firing activity through CB1 agonists and FAAH inhibitors -- Involvement of serotonergic system in cannabinoid analgesia -- Cannabinoids, monoamines, COMT and schizophrenia: pathobiological mechanisms in psychosis."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1411312578>
schema:genre"Electronic books"
schema:inLanguage"en"
schema:name"Endocannabinoid regulation of monoamines in psychiatric and neurological disorders"
schema:publication
schema:publisher
schema:url<http://site.ebrary.com/id/10733550>
schema:url<http://dx.doi.org/10.1007/978-1-4614-7940-6>
schema:url<http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=606343>
schema:url<http://lib.myilibrary.com?id=517034>
schema:workExample
schema:workExample
wdrs:describedby

Content-negotiable representations

關閉視窗

請登入WorldCat 

没有帳號嗎?你可很容易的 建立免費的帳號.